search
Back to results

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

Primary Purpose

Major Depressive Disorder

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Vortioxetine 10-20 mg
Placebo
SSRI
Sponsored by
H. Lundbeck A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient has achieved either partial (some symptoms of a MDE are present but full criteria are not met) or full remission of major depressive disorder (MDD), diagnosed according to DSM-IV-TR™.
  • The patient has HAMD-17 total score ≤10.
  • The patient has received SSRI monotherapy for the MDE from which the patient is currently in full or partial remission for ≥12 weeks at licensed doses and been on stable dose ≥8 weeks prior to Screening Visit.
  • The patient has ≥50% response to current SSRI treatment (Antidepressant Treatment Response Questionnaire [ATRQ]).
  • The patient has a PDQ-D total score >25.
  • The patient is a man or woman, aged ≥18 and ≤65 years.

Exclusion Criteria:

  • The patient has a score ≥70 on the DSST (numbers of correct symbols) at the Baseline Visit.
  • The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit.
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient has a history of lack of response to previous adequate treatment with vortioxetine.
  • The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using Mini International Neuropsychiatric Interview (MINI).
  • The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of the depressive episode from which the patient is currently in full or partial remission (DSM-IV-TR™ criteria).
  • The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria).
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria).

Other protocol-defined inclusion and exclusion criteria may apply.

Sites / Locations

  • EE001
  • EE002
  • FI002
  • FI003
  • FI005
  • FI001
  • FI006
  • FI004
  • DE002
  • DE001
  • DE005
  • DE003
  • DE004
  • RS002
  • RS001
  • SK003
  • SK002

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Vortioxetine 10-20 mg

Vortioxetine 10-20 mg + SSRI

SSRI

Arm Description

daily, encapsulated, orally

daily, encapsulated, orally

licensed doses, encapsulated, orally

Outcomes

Primary Outcome Measures

Change in Digit Symbol Substitution Test (DSST): number of correct symbols

Secondary Outcome Measures

Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])
Change in Trail Making Test (TMT) score: TMT-A; speed of processing
Change in TMT score: TMT-B; executive functioning
Change in reaction time score: Choice Reaction Time (CRT); attention
Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed
Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning
Change in STROOP: congruent score; speed of processing
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score
Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score
Change in Clinical Global Impression - Severity of Illness (CGI-S)
Clinical Global Impression - Global Improvement (CGI-I) score
Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score
Number of adverse events
Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)

Full Information

First Posted
October 21, 2014
Last Updated
May 23, 2017
Sponsor
H. Lundbeck A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT02279953
Brief Title
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
Official Title
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
H. Lundbeck A/S

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
151 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vortioxetine 10-20 mg
Arm Type
Experimental
Arm Description
daily, encapsulated, orally
Arm Title
Vortioxetine 10-20 mg + SSRI
Arm Type
Experimental
Arm Description
daily, encapsulated, orally
Arm Title
SSRI
Arm Type
Experimental
Arm Description
licensed doses, encapsulated, orally
Intervention Type
Drug
Intervention Name(s)
Vortioxetine 10-20 mg
Other Intervention Name(s)
Brintellix®, Lu AA21004
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Type
Drug
Intervention Name(s)
SSRI
Intervention Description
escitalopram, citalopram or sertraline
Primary Outcome Measure Information:
Title
Change in Digit Symbol Substitution Test (DSST): number of correct symbols
Time Frame
Baseline to Week 8
Secondary Outcome Measure Information:
Title
Change in Rey Auditory Verbal Learning Test (RAVLT) score: memory (delayed recall) and learning [acquisition])
Time Frame
Baseline to Week 8
Title
Change in Trail Making Test (TMT) score: TMT-A; speed of processing
Time Frame
Baseline to Week 8
Title
Change in TMT score: TMT-B; executive functioning
Time Frame
Baseline to Week 8
Title
Change in reaction time score: Choice Reaction Time (CRT); attention
Time Frame
Baseline to Week 8
Title
Change in reaction time score: Simple Reaction Time (SRT); psychomotor speed
Time Frame
Baseline to Week 8
Title
Change in Stroop Colour Naming Test (STROOP): incongruent score; executive functioning
Time Frame
Baseline to Week 8
Title
Change in STROOP: congruent score; speed of processing
Time Frame
Baseline to Week 8
Title
Change in Perceived Deficits Questionnaire - Depression (PDQ-D) total score
Time Frame
Baseline to Week 8
Title
Change in Hamilton Depression Rating Scale-17 (HAMD-17) total score
Time Frame
Baseline to Week 8
Title
Change in Clinical Global Impression - Severity of Illness (CGI-S)
Time Frame
Baseline to Week 8
Title
Clinical Global Impression - Global Improvement (CGI-I) score
Time Frame
Week 8
Title
Change in University of San Diego Performance-based Skills Assessment - Brief (UPSA-B) total score
Time Frame
Baseline to Week 8
Title
Number of adverse events
Time Frame
Baseline to Week 12
Title
Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions (1, 2, 3, 4 and 7)
Time Frame
Baseline to Week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient has achieved either partial (some symptoms of a MDE are present but full criteria are not met) or full remission of major depressive disorder (MDD), diagnosed according to DSM-IV-TR™. The patient has HAMD-17 total score ≤10. The patient has received SSRI monotherapy for the MDE from which the patient is currently in full or partial remission for ≥12 weeks at licensed doses and been on stable dose ≥8 weeks prior to Screening Visit. The patient has ≥50% response to current SSRI treatment (Antidepressant Treatment Response Questionnaire [ATRQ]). The patient has a PDQ-D total score >25. The patient is a man or woman, aged ≥18 and ≤65 years. Exclusion Criteria: The patient has a score ≥70 on the DSST (numbers of correct symbols) at the Baseline Visit. The patient is, in the opinion of the investigator, not able to complete the neuropsychological tests validly at the Baseline Visit. The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests. The patient is diagnosed with reading disability (dyslexia). The patient has a history of lack of response to previous adequate treatment with vortioxetine. The patient has any current psychiatric disorder or Axis I disorder (according to DSM-IV-TR™ criteria) other than MDD, as assessed using Mini International Neuropsychiatric Interview (MINI). The patient has a current or has had a diagnosis of dysthymic disorder within 3 months preceding the onset of the depressive episode from which the patient is currently in full or partial remission (DSM-IV-TR™ criteria). The patient has borderline, schizotypal, schizoid, paranoid, histrionic, antisocial personality disorders (axis II) as comorbid or primary diagnosis (DSM-IV-TR™ criteria). The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria). The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features (DSM-IV-TR™ criteria). Other protocol-defined inclusion and exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Email contact via H. Lundbeck A/S
Organizational Affiliation
LundbeckClinicalTrials@lundbeck.com
Official's Role
Study Director
Facility Information:
Facility Name
EE001
City
Tallinn
Country
Estonia
Facility Name
EE002
City
Tallinn
Country
Estonia
Facility Name
FI002
City
Helsinki
Country
Finland
Facility Name
FI003
City
Helsinki
Country
Finland
Facility Name
FI005
City
Helsinki
Country
Finland
Facility Name
FI001
City
Kuopio
Country
Finland
Facility Name
FI006
City
Kupio
Country
Finland
Facility Name
FI004
City
Turku
Country
Finland
Facility Name
DE002
City
Berlin
Country
Germany
Facility Name
DE001
City
Bielefeld
Country
Germany
Facility Name
DE005
City
Bochum
Country
Germany
Facility Name
DE003
City
Frankfurt
Country
Germany
Facility Name
DE004
City
Mittweida
Country
Germany
Facility Name
RS002
City
Belgrade
Country
Serbia
Facility Name
RS001
City
Kragujevac
Country
Serbia
Facility Name
SK003
City
Levice
Country
Slovakia
Facility Name
SK002
City
Rimavska Sobota
Country
Slovakia

12. IPD Sharing Statement

Links:
URL
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000229-19/results
Description
Results EudraCT 2014-000229-19

Learn more about this trial

Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

We'll reach out to this number within 24 hrs